FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206541643> ?p ?o ?g. }

• W4206541643 abstract "CTL with optimal effector function play critical roles in mediating protection against various intracellular infections and cancer. However, individuals may exhibit suppressive immune microenvironment and, in contrast to activating CTL, their autologous antigen presenting cells may tend to tolerize or anergize antigen specific CTL. As a result, although still in the experimental phase, CTL-based adoptive immunotherapy has evolved to become a promising treatment for various diseases such as cancer and virus infections. In initial experiments ex vivo expanded CMV (cytomegalovirus) specific CTL have been used for treatment of CMV infection in immunocompromised allogeneic bone marrow transplant patients. While it is common to have life-threatening CMV viremia in these patients, none of the patients receiving expanded CTL develop CMV related illness, implying the anti-CMV immunity is established by the adoptively transferred CTL1. Promising results have also been observed for melanoma and may be extended to other types of cancer2. While there are many ways to ex vivo stimulate and expand human CTL, current approaches are restricted by the cost and technical limitations. For example, the current gold standard is based on the use of autologous DC. This requires each patient to donate a significant number of leukocytes and is also very expensive and laborious. Moreover, detailed in vitro characterization of DC expanded CTL has revealed that these have only suboptimal effector function 3. Here we present a highly efficient aAPC based system for ex vivo expansion of human CMV specific CTL for adoptive immunotherapy (Figure 1). The aAPC were made by coupling cell sized magnetic beads with human HLA-A2-Ig dimer and anti-CD28mAb4. Once aAPC are made, they can be loaded with various peptides of interest, and remain functional for months. In this report, aAPC were loaded with a dominant peptide from CMV, pp65 (NLVPMVATV). After culturing purified human CD8+ CTL from a healthy donor with aAPC for one week, CMV specific CTL can be increased dramatically in specificity up to 98% (Figure 2) and amplified more than 10,000 fold. If more CMV-specific CTL are required, further expansion can be easily achieved by repetitive stimulation with aAPC. Phenotypic and functional characterization shows these expanded cells have an effector-memory phenotype and make significant amounts of both TNFα and IFNγ (Figure 3)." @default.
• W4206541643 created "2022-01-26" @default.
• W4206541643 creator A5001846907 @default.
• W4206541643 creator A5031478873 @default.
• W4206541643 creator A5061137097 @default.
• W4206541643 date "2011-04-11" @default.
• W4206541643 modified "2023-09-28" @default.
• W4206541643 title "HLA-Ig Based Artificial Antigen Presenting Cells for Efficient <em>ex vivo</em> Expansion of Human CTL" @default.
• W4206541643 doi "https://doi.org/10.3791/2801-v" @default.
• W4206541643 hasPublicationYear "2011" @default.
• W4206541643 type Work @default.
• W4206541643 citedByCount "0" @default.
• W4206541643 crossrefType "journal-article" @default.
• W4206541643 hasAuthorship W4206541643A5001846907 @default.
• W4206541643 hasAuthorship W4206541643A5031478873 @default.
• W4206541643 hasAuthorship W4206541643A5061137097 @default.
• W4206541643 hasBestOaLocation W42065416431 @default.
• W4206541643 hasConcept C147483822 @default.
• W4206541643 hasConcept C147969180 @default.
• W4206541643 hasConcept C150903083 @default.
• W4206541643 hasConcept C167672396 @default.
• W4206541643 hasConcept C203014093 @default.
• W4206541643 hasConcept C207001950 @default.
• W4206541643 hasConcept C2522874641 @default.
• W4206541643 hasConcept C26291073 @default.
• W4206541643 hasConcept C2776090121 @default.
• W4206541643 hasConcept C2777701055 @default.
• W4206541643 hasConcept C2779820661 @default.
• W4206541643 hasConcept C2780674031 @default.
• W4206541643 hasConcept C71924100 @default.
• W4206541643 hasConcept C86803240 @default.
• W4206541643 hasConcept C8891405 @default.
• W4206541643 hasConcept C90375314 @default.
• W4206541643 hasConceptScore W4206541643C147483822 @default.
• W4206541643 hasConceptScore W4206541643C147969180 @default.
• W4206541643 hasConceptScore W4206541643C150903083 @default.
• W4206541643 hasConceptScore W4206541643C167672396 @default.
• W4206541643 hasConceptScore W4206541643C203014093 @default.
• W4206541643 hasConceptScore W4206541643C207001950 @default.
• W4206541643 hasConceptScore W4206541643C2522874641 @default.
• W4206541643 hasConceptScore W4206541643C26291073 @default.
• W4206541643 hasConceptScore W4206541643C2776090121 @default.
• W4206541643 hasConceptScore W4206541643C2777701055 @default.
• W4206541643 hasConceptScore W4206541643C2779820661 @default.
• W4206541643 hasConceptScore W4206541643C2780674031 @default.
• W4206541643 hasConceptScore W4206541643C71924100 @default.
• W4206541643 hasConceptScore W4206541643C86803240 @default.
• W4206541643 hasConceptScore W4206541643C8891405 @default.
• W4206541643 hasConceptScore W4206541643C90375314 @default.
• W4206541643 hasIssue "50" @default.
• W4206541643 hasLocation W42065416431 @default.
• W4206541643 hasOpenAccess W4206541643 @default.
• W4206541643 hasPrimaryLocation W42065416431 @default.
• W4206541643 hasRelatedWork W1994953654 @default.
• W4206541643 hasRelatedWork W2035649284 @default.
• W4206541643 hasRelatedWork W2111140175 @default.
• W4206541643 hasRelatedWork W2114785263 @default.
• W4206541643 hasRelatedWork W2140647949 @default.
• W4206541643 hasRelatedWork W2401195345 @default.
• W4206541643 hasRelatedWork W3194933657 @default.
• W4206541643 hasRelatedWork W4295214918 @default.
• W4206541643 hasRelatedWork W4312297876 @default.
• W4206541643 hasRelatedWork W90702616 @default.
• W4206541643 isParatext "false" @default.
• W4206541643 isRetracted "false" @default.
• W4206541643 workType "article" @default.